Please go to the PowerPak homepage
and select a course.
Addressing Challenges With Anti-VEGF Access
Provided by Evolve Medical Education
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals.
Nathan Steinle, MD (Moderator)
California Retina Consultants
Santa Barbara, CA
David Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani
College of Medicine
Director of Research, Retina Vitreous Associates of Florida
Sean Goodale, CPA, MBA
Chief Executive Officer
Kansas City, MO
Alison L. Ratliff, MBA
Chief Executive Officer
South Coast Retina Center
Santa Barbara, CA
This webinar is designed to address the challenges related to anti-VEGF access in retina practices. Hosted by retina specialists and retinal practice CEOs, the program will tackle both clinical and business-related issues including step therapy, MACRA/MIPS, payor-related obstacles, and more. A previously recorded, live question-and-answer session will answer many of your questions and concerns.
This certified CME activity is designed for retina specialists, ophthalmologists, pharmacists and other professionals involved in the treatment and management of patients with retinal disorders.
MAY 12, 2020
MAY 12, 2021
Upon completion of this activity, the participant should be able to:
- Implement the most up-to-date decision-making tools to determine optimal treatment for each patient and improve communication with patients about their treatment options.
- Advocate against prior authorizations and step policies and learn how to appeal them.
The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE UAN 0062-9999-20-126-H01-P, 1-hour home study credit (0.1 CEU)
This application-based activity is accredited for 1 home study contact hour (0.1 CEU) for pharmacists. To claim credit, participants must sign-in/register and participate in the entire activity. No partial credit will be issued.
How to Earn Credit
Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for
each answer then proceed to the next question. Once completed, click on the
Grade Exam button at the bottom of the page. Your posttest will
automatically be graded. If you successfully complete the posttest (score
of 75% or higher), your statement of participation will be made available
immediately. Click on the View Statement of Participation link and print
the statement for your records. If you receive a score lower than 75%, you
will receive a message notifying you that you did not pass the posttest.
You will have 2 opportunities to pass the posttest. To receive Credit, you
must provide your date of birth and NABP number. All Credit information
will be uploaded into CPE monitor within 30 days.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Nathan Steinle, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, Novartis and Regeneron Pharmaceuticals; Grant Research Support: Genentech, Novartis and Regeneron Pharmaceuticals; Speaker: Genentech, Novartis and Regeneron Pharmaceuticals
David Eichenbaum, MD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, DORC, Eyepoint Pharmaceuticals, Genentech, Gyroscope, Kodiak, Novartis, Recens Medical, and Regeneron Pharmaceuticals; Grant/Research Support: Alimera, Allergan, Chengdu, Clearside Biomedical, Genentech, Gyroscope, Kodiak, Mylan, NGM, Novartis, Opthea, and Ophthotech; Speaker: Allergan, Genentech, and Novartis; Stock/Shareholder: Boston Image Reading Center, Clearside Biomedical, Hemera Biosciences, and Network Eye.
Sean Goodale, CPA, MBA, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker: Genentech, Regeneron Pharmaceuticals.
Alison L. Ratliff, MBA, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Novartis, and Regenxbio; Speaker: Genentech, Regeneron Pharmaceuticals.
EDITORIAL SUPPORT DISCLOSURES
The staff and planners involved in this activity have no financial relationships with commercial interests.
Caitlin Mardis, PharmD, University of South Carolina College of Pharmacy staff has nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The University of South Carolina College of Pharmacy, or Regeneron Pharmaceuticals.